Seres Therapeutics Inc (MCRB)vsModerna Inc (MRNA)
MCRB
Seres Therapeutics Inc
$5.01
-1.76%
HEALTHCARE · Cap: $51.23M
MRNA
Moderna Inc
$143.97
+5.38%
HEALTHCARE · Cap: $56.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 118222% more annual revenue ($2.23B vs $1.88M). MCRB leads profitability with a 0.0% profit margin vs -141.4%. MRNA earns a higher WallStSmart Score of 21/100 (F).
MCRB
Avoid20
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for MCRB.
Margin of Safety
+70.0%
Fair Value
$134.97
Current Price
$143.97
$9.00 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
Smaller company, higher risk/reward
0.0% margin — thin
Elevated debt levels
ROE of -177.0% — below average capital efficiency
Trading at 8.5x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MCRB
The strongest argument for MCRB centers on Price/Book.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : MCRB
The primary concerns for MCRB are Market Cap, Profit Margin, Debt/Equity. Debt-to-equity of 1.64 is elevated, increasing financial risk.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
MCRB profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.
MRNA carries more volatility with a beta of 1.11 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
MCRB generates stronger free cash flow (-22M), providing more financial flexibility.
Bottom Line
MRNA scores higher overall (21/100 vs 20/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Seres Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Seres Therapeutics, Inc., a microbiome therapeutic platform company, is involved in the development of bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company is headquartered in Cambridge, Massachusetts.
Visit Website →Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?